Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670839 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL2825852 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6406357 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL2825850 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL13207340 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6744832 | 0.85 | TDP1 (0.73) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6744829 | 0.85 | TDP1 (0.73) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL7014287 | 0.83 | TDP1 (0.71) | TDP1MAPTALDH1A1LRRK2IDO1 | |
| SCHEMBL7006381 | 0.82 | TDP1 (0.69) | TDP1MAPTALDH1A1LRRK2IDO1 | |
| SCHEMBL5468788 | 0.81 | TDP1 (0.68) | TDP1MAPTALDH1A1LRRK2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012026982-A1 | ULTRASOUND-ENHANCED STENOSIS THERAPY | WALLACE MICHAEL P (US) | 2012-03-01 | — | — | WO | claimed |
| US-20110082414-A1 | Ultrasound-enhanced stenosis therapy | CARDIOPROLIFIC INC. | 2011-04-07 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20060212109-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION (US) | 2006-09-21 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| US-7083642-B2 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION (US) | 2006-08-01 | — | — | US | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-20030139801-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION (US) | 2003-07-24 | — | — | US | claimed |
| US-20030050692-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION | 2003-03-13 | — | — | US | claimed |
| JP-11246404-A | — | — | None | — | — | JP | disclosed |
| US-20250205467-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER USING ULTRASOUND | DUKE UNIVERSITY | 2025-06-26 | — | — | US | disclosed |
| US-11364043-B2 | Methods and devices for endovascular therapy | CARDIOPROLIFIC INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-11116528-B2 | Methods and devices for endovascular therapy | CARDIOPROLIFIC, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11039845-B2 | Methods and devices for endovascular therapy | CARDIOPROLIFIC INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-0816338-B1 | 3-(BIS-SUBSTITUTED-PHENYLMETHYLENE)OXINDOLE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5977130-A | CARDIOVASCULAR DISORDERS | TAIHO PHARMEUTICAL CO., LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5965600-A | 3-(bis-substituted phenylmethylene) oxindole derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-12 | — | — | US | disclosed |
| JP-H11246404-A | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORBABILITY | TAIHO YAKUHIN KOGYO KK | 1999-09-14 | — | — | JP | disclosed |
| EP-0815859-A1 | INTIMAL THICKENING INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0816338-A1 | 3-(BIS-SUBSTITUTED-PHENYLMETHYLENE)OXINDOLE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | TDP1 2879/4885MAPT 1309/4885ALDH1A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.